

Active substances set

Search phrase: obinutuzumab

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

non-Hodgkin lymphoma

Obinutuzumab	Obinutuzumab in combination with chemotherapy, followed by Obinutuzumab maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced FL. Obinutuzumab in combination with bendamustine followed by Obinutuzumab maintenance is indicated for the treatment of patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.	FULL REIMBURSEMENT ESMO

Chronic lymphoid leukemia

Obinutuzumab	Obinutuzumab in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated CLL and with comorbidities making them unsuitable for full-dose fludarabine based therapy.	REIMBURSEMENT WITH RESTRICTIONS ESMO